Triamcinolone hexacetonide
(Synonyms: 己曲安奈德) 目录号 : GC33897
Triamcinolonehexacetonide是一种常用的长效类固醇，用于治疗亚急性和慢性炎性关节疾病。
Cas No.:5611-51-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Animal experiment: | Guinea pigs: Animals are given intraarticular injection of 0.1 mL of Triamcinolone hexacetonide provided a dose of 0.40 mg/kg (groups 2 and 3) or 0.04 mg/kg (groups 4 and 5). The volume of CMC injected into the knees of group 6 animals is the same as that used for the intraarticular injections in the other groups, i.e., 0.1 mL. When the animals are killed, both knees are immediately opened and examined grossly[1]. |
References: [1]. Williams JM, et al. Triamcinolone hexacetonide protects against fibrillation and osteophyte formation following chemically induced articular cartilage damage. Arthritis Rheum. 1985 Nov;28(11):1267-74. | |
Triamcinolone hexacetonide is a commonly used long-acting steroids in treatment of subacute and chronic inflammatory joint diseases.
Triamcinolone hexacetonide produces a marked, dose-dependent protective effect in the model of chemically induced articular cartilage damage. Guinea pig injected with Triamcinolone hexacetonide shows much less prominent fibrillation and osteophytes. Cell loss is less extensive. A single injection of Triamcinolone hexacetonide into the ipsilateral knee of rabbits which have been subjected to partial lateral meniscectomy and transection of the sesamoid and collateral fibular ligaments reduces chondrocyte cloning, loss of cells, osteophyte formation, and fibrillation[1]. The half-life of commercially available Triamcinolone hexacetonide in the vitreous is double that of Triamcinolone hexacetonide, but the former is toxic to the retina in this rabbit model. Reformulated iso-osmolar Triamcinolone hexacetonide shows no evidence of deleterious effects to retina function or structure[2]. Local application of Triamcinolone hexacetonide at a site of lingual nerve injury leads to changes that are potentially beneficial such as reduced mechanical sensitivity and enhanced regeneration[3].
[1]. Williams JM, et al. Triamcinolone hexacetonide protects against fibrillation and osteophyte formation following chemically induced articular cartilage damage. Arthritis Rheum. 1985 Nov;28(11):1267-74. [2]. Abd-El-Barr MM, et al. Safety and pharmokinetics of triamcinolone hexacetonide in rabbit eyes. J Ocul Pharmacol Ther. 2008 Apr;24(2):197-205. [3]. Yates JM, et al. The effect of triamcinolone hexacetonide on the spontaneous and mechanically-induced ectopic discharge following lingual nerve injury in the ferret. Pain. 2004 Oct;111(3):261-9.
| Cas No. | 5611-51-8 | SDF | |
| 别名 | 己曲安奈德 | ||
| Canonical SMILES | O=C([C@]([C@@]1([H])C[C@@]2([H])[C@@](CCC3=CC4=O)([H])[C@@](F)([C@]3(C=C4)C)[C@@H](O)C5)(OC(C)(C)O1)[C@]25C)COC(CC(C)(C)C)=O | ||
| 分子式 | C30H41FO7 | 分子量 | 532.64 |
| 溶解度 | DMSO : 41.67 mg/mL (78.23 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8774 mL | 9.3872 mL | 18.7744 mL |
| 5 mM | 0.3755 mL | 1.8774 mL | 3.7549 mL |
| 10 mM | 0.1877 mL | 0.9387 mL | 1.8774 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Intra-articular injection with platelet-rich plasma compared to Triamcinolone hexacetonide or saline solution in knee osteoarthritis: A double blinded randomized controlled trial with one year follow-up
Clin Rehabil 2022 Jul;36(7):900-915.PMID:35379019DOI:10.1177/02692155221090407.
Objectives: To compare the effectiveness of intra-articular injection (IAI) of Platelet-Rich Plasma (PRP) with Triamcinolone hexacetonide (TH) and Saline Solution (SS), in patients with knee osteoarthritis (OA). Design: A randomized controlled trial, with blinded patients and assessor. Setting: Outpatient rheumatology service. Subjects: Patients with knee osteoarthritis grades II and III. Interventions: Patients received IAI with PRP, 40 mg TH, or SS. Methods: Patients were assessed at baseline and after 4, 8, 12 e 52 weeks with: visual analogue scale (VAS) for pain at rest and movement, WOMAC questionnaire, Timed to Up and Go test, 6-min walk test, percentage of improvement, goniometry, quality of life SF-36 questionnaire, Likert scale and Kelgreen & Lawrence (KL) radiographic scale (only at baseline and 52 weeks). Results: 100 patients were studied, with a mean age of 67.13(6.56) years. The TH group was superior for: percentage of improvement (versus SS group from 4 to 52 weeks); WOMAC total and pain (versus PRP group at 4 weeks); and WOMAC stiffness (versus SS group at 12 weeks). The SS group was inferior for WOMAC function (from 8 to 52 weeks). The PRP group showed lowest radiographic progression [TH 17 (51.51%) to 24 (72.72%); SS 17 (51.51%) to 30 (90.90%); PRP 20 (58.82%) to 21 (61.76%)]. Conclusion: The Triamcinolone hexacetonide group was superior for percentage of improvement and WOMAC, pain and stiffness. For the WOMAC function, the Platelet-Rich Plasma group and Triamcinolone hexacetonide group were superior to the Saline group. The Platelet-Rich Plasma group showed the lowest radiographic progression at 52 weeks of follow-up.
Data evaluating triamcinolone acetonide and Triamcinolone hexacetonide loaded poly(δ-valerolactone- co-allyl-δ-valerolactone) microparticles
Data Brief 2023 Mar 1;48:109032.PMID:36950558DOI:10.1016/j.dib.2023.109032.
Advanced drug delivery strategies can be used to enhance the therapeutic effectiveness of locally delivered corticosteroids. Poly(δ-valerolactone-co-allyl-δ-valerolactone) microparticles (PVL-co-PAVL MPs) were evaluated for delivery of two corticosteroids, triamcinolone acetonide and Triamcinolone hexacetonide. PVL-co-PAVL MPs were prepared using a modified oil-in-water emulsification method, followed by a UV-initiated cross-linking process. The resulting PVL-co-PAVL MPs were purified with an excess amount of water and then acetone to remove residual surfactant, cross-linker, and catalyst before lyophilization. Triamcinolone acetonide and Triamcinolone hexacetonide were independently loaded into the resulting PVL-co-PAVL MPs via a post-loading swelling-equilibrium method. The drug-loaded MPs were characterized in terms of drug loading (determined by high-performance liquid chromatography, HPLC), thermal properties (determined by differential scanning calorimetry, DSC), and in vitro drug release kinetics (with quantification of drug using HPLC) to better understand the suitability of PVL-co-PAVL MPs for delivery of corticosteroids. These data demonstrate the potential of PVL-co-PAVL MPs as a promising drug delivery platform for the sustained release of corticosteroids. Raw data have been made available on Mendeley Data. Additional details on PVL-co-PAVL MPs were previously reported [1].
Comparison of efficacy between triamcinolone acetonide and Triamcinolone hexacetonide for intraarticular therapy in juvenile idiopathic arthritis: a retrospective analysis
BMC Rheumatol 2022 Mar 31;6(1):18.PMID:35354497DOI:10.1186/s41927-022-00249-z.
Background: There are many FDA-approved corticosteroid preparations available for intra-articular injection, however Triamcinolone hexacetonide is not one of them. It was the intraarticular drug of choice among pediatric rheumatologists up until approximately a decade ago, when production of this medication ceased. It can be obtained in the United States and Canada via importation from Europe, but it is not FDA-approved at this time. We wish to compare the duration of remission of intraarticular Triamcinolone hexacetonide (TH) with that of triamcinolone acetonide (TA) in children with juvenile idiopathic arthritis (JIA) and demonstrate its safety in this population. Methods: This retrospective chart review included 39 patients with JIA who received intraarticular corticosteroid injections (IACIs) from September 2018 to September 2019. These patients were reviewed and their life-time injections with either TH (41 joints) or TA (124 joints) was noted through May 30, 2021. Patients with concomitant systemic therapy initiation were excluded. The primary outcome was time to relapse. Relapse was defined by the presence of arthritis on physical examination by an attending rheumatologist. Kaplan-Meier curves and a log-rank test were constructed to compare the probability of time to relapse between IACI injections. Additionally, mixed effects cox regression models were constructed to account for multiple injections per participant. Results: Kaplan-Meier estimator of median relapse time in months was higher for TH. Based on the log-rank test, TA joints had a higher probability of experiencing a relapse during the study time (p value < 0.001). The hazard of time to relapse was reduced when comparing TH to TA in both unadjusted and adjusted mixed effects cox regression models [unadjusted hazard ratio (95% confidence interval): 0.184 (0.089, 0.381); adjusted hazard ratio (95% confidence interval): 0.189 (0.092, 0.386)]. Conclusions: TH has longer duration of action than TA and is associated with less systemic side effects. It should be considered the drug of choice for intraarticular corticosteroid injections in children with JIA.
Intra-articular Triamcinolone hexacetonide injections in hands osteoarthritis ‒ A double-blinded randomized controlled trial with a one year follow-up
Clinics (Sao Paulo) 2022 Jul 26;77:100036.PMID:35905573DOI:10.1016/j.clinsp.2022.100036.
Objective: to evaluate the effectiveness of Triamcinolone hexacetonide (TH) Intra-Articular Injection (IAI) in hand Interphalangeal Joints (IP) of Osteoarthritis (OA) patients to improve pain and joint swelling; improve function, goniometry, and grasping force, and assess IAI influence on radiographic evolution over 1-year. Methods: A randomized, double-blind study. 60 patients who underwent IAI at the most symptomatic IP joint were randomly assigned to receive TH+Lidocaine (LD) (TH/LD group) or just LD (LD group). Patients were assessed blindly for 1-year, at baseline and 1, 4, 8, 12, and 48 weeks. The following variables were assessed: articular pain and swelling, AUSCAN and COCHIN functional questionnaires, grip and pinch strength, goniometry, perception of improvement, acetaminophen consumption, and simple radiography. Repeated-measures ANOVA test was used to analyze the intervention response. Results: Sixty patients completed the follow-up. There were nine missed assessments. 97% were women; mean age of 61-years (SD = 8.2), and approximately 5-years of disease (SD = 3.6). Half of the patients present radiographic classification Kellgren and Lawrence (KL) grades I and II, and the other half grades III and IV. The two groups evolved similarly at 48-weeks. TH/LD group had a better evaluation in joint swelling and acetaminophen consumption (p = 0.04 and p < 0.001, respectively) at 48-weeks. Radiographically there was no statistical difference between groups (KL, p = 0.564; erosive OA, p = 0.999; worsening, p = 0.573). Conclusion: The IAI IP hands OA is effective for the improvement of joint swelling and decrease of analgesic consumption and does not influence the radiographic evolution of the injected joint.
Retraction: Intra-articular injections with either Triamcinolone hexacetonide, stanozolol, hylan G-F 20, or a platelet concentrate improve clinical signs in police working dogs with bilateral hip osteoarthritis
Front Vet Sci 2023 Jan 18;9:1130041.PMID:36744223DOI:10.3389/fvets.2022.1130041.
[This retracts the article DOI: 10.3389/fvets.2020.609889.].